跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT07351929
NCT07351929进行中（未招募）不适用

An Emotional-distress-based Integrated Care Programme in Patients With an Acute Exacerbation of COPD (EmoD) - A Feasibility Study

University of Zurich1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2026年1月12日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
干预措施

试验速览

阶段
不适用
状态
进行中（未招募）
入组人数
20
试验地点
1
主要终点
Change in COPD-related emotional distress (CRED)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The investigators have developed a new counseling service that focuses on the emotional distress experienced by people living with COPD. The service has been specially developed for patients who have experienced a deterioration in their lung condition (known as an acute exacerbation of COPD). The new program is led by an APN team. Other professionals are involved in the program, such as medical staff and physiotherapists. The new counseling service lasts three months. Patients will receive ten counseling sessions with a specialized nurse.

The overall objective of the study is to assess the feasibility of the newly developed emotional-distress-based integrated care programme.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Patients with a confirmed diagnosis of COPD (GOLD 1-4)
  • •Hospitalisation due to a COPD exacerbation and decision to start with steroids and/or antibiotics (severe exacerbation)
  • •Inpatient on the pneumology or medical ward

排除标准

  • •Cognitive impairment (dementia, delirium) (DOS>3 or AES>6 or Mini-Cog<3)
  • •Unstable psychiatric disorders
  • •Not speaking German
  • •Lung transplant
  • •Pneumonia caused by chronic colonization by bacteria (Legionella, nontuberculous mycobacteria (NTM))
  • •Unable to telephone

研究组 & 干预措施

Intervention Group

Experimental

干预措施: EmoD Intervention (Other)

结局指标

主要结局

Change in COPD-related emotional distress (CRED)

时间窗: Quantitative data will be collected baseline, in the first month after hospitalization due to AECPOD (MZP 1, week 0-4), and follow-up, three months after (MZP2, week 14-17)

Change in COPD-related emotional distress between baseline and month 3. COPD-related emotional distress will be assessed using the newly developed 'COPD-Related Emotional Distress Questionnaire (CRED)', which was developed for CF and COPD patients (publication in progress; former name of the questionnaire: IRED-RESP). The questionnaire includes 36 items and assesses distress related to symptoms, treatment, restrictions in range of mobility and participation in social life, unpredictability of the disease, and stigma, using a 5-point Likert scale. Higher scores mean more emotional distress (worse outcome).

次要结局

  • Reach: Total number of patients who take up the programme(Four months)
  • Reach: Percentage of patients who take part in at least one outpatient intervention(Four months)
  • Reach: Reasons for participating in the programme (facilitators and barriers)(Four months)
  • Reach: Reasons for ending (prematurely or on schedule) the programme (facilitators and barriers)(Four months)
  • Potential effectiveness: Change in depression(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Change in anxiety(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Change in health-related quality of life (QoL)(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Patient satisfaction with programme(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Number of moderate exacerbations within 3 months(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Number of severe exacerbations within 3 months(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Rehospitalisation at day 90(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Time until first rehospitalisation(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Change in health behaviour smoking- current status(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Change in health behaviour smoking - ex- smoker(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Change in health behaviour smoking -smoker(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Change in health behaviour nutrition - body weight(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Change in health behaviour nutrition - body height(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Change in health behaviour nutrition - BMI(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Change in health behaviour nutrition - NRS(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Change in health behaviour physical activity - C-PPAC(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Change in health behaviour physical activity - PR(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Change in health behaviour inhalation adherence(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Change in health behaviour action plan(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Potential effectiveness: Change in health behaviour oxygen use(Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).)
  • Implementation: Percent of programme components carried out according to the intervention manual(Data will be collected at the earliest six months after the start of the programme)
  • Implementation: Acceptability of the programme(Data will be collected at the earliest six months after the start of the programme)
  • Implementation: Appropriateness of the programme(Data will be collected at the earliest six months after the start of the programme)
  • Implementation: Feasibility of the programme(Data will be collected at the earliest six months after the start of the programme)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

尚未招募
不适用
Cost-effectiveness and Implementation of a Transdiagnostic Internet-based Intervention for Emotional Disorders in Community Care.Anxiety Disorders
NCT07345117Universitat Jaume I200
招募中
不适用
Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET)
NCT07282392University of Utah30
已完成
不适用
Experimental Study on Exercise and Well-being in University Students
NCT07275398Università degli Studi di Brescia91
尚未招募
不适用
The ECHO Study: Compassion-focused Therapy for Young Voice Hearers and Their Caregivers
NCT07314515University of Southern Denmark80
进行中（未招募）
不适用
The Effects of Group Social Work Intervention on Children's Emotional Intelligence, Emotion Regulation Skills and Empathy Tendencies
NCT07273786Selcuk University38